Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma

Abstract excerpt

Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Corneal surgery and disorders
• Share to Glaucoma and retinal disorders
• Share to Retinal Diseases and Treatments